Andreas Reiter Selected Research

BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative)

9/2010	Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.
6/2009	Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
4/2005	The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas Reiter Research Topics

Disease

39	Neoplasms (Cancer) 08/2022 - 02/2009
29	Systemic Mastocytosis 11/2022 - 08/2011
23	Eosinophilia 02/2022 - 07/2004
10	Mastocytosis 01/2022 - 12/2012
8	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 08/2022 - 01/2002
8	Primary Myelofibrosis (Myelosclerosis) 10/2021 - 02/2007
8	Myeloproliferative Disorders (Myeloproliferative Disorder) 01/2012 - 09/2005
7	Hypersensitivity (Allergy) 01/2022 - 06/2019
7	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2022 - 07/2004
7	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 04/2005
7	Polycythemia Vera 01/2018 - 04/2006
6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 04/2005
6	Pdgfra-Associated Chronic Eosinophilic Leukemia 10/2014 - 07/2004
5	Leukemia 01/2022 - 03/2011
5	Splenomegaly 01/2018 - 02/2011
4	Mast-Cell Leukemia (Leukemia, Mast Cell) 01/2021 - 09/2013
4	Thrombocytopenia (Thrombopenia) 11/2019 - 01/2012
4	Anemia 11/2019 - 02/2011
3	Hereditary alpha-tryptasemia syndrome 01/2022 - 01/2021
3	Mast Cell Activation Disorders (Mast-Cell Disease) 01/2022 - 01/2020
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2017 - 10/2006
3	Acute Promyelocytic Leukemia 08/2012 - 04/2005
3	BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative) 09/2010 - 04/2005
3	Genetic Translocation (Chromosomal Translocation) 01/2008 - 04/2005
2	Thrombocytosis (Thrombocythemia) 01/2021 - 10/2016
2	Blast Crisis (Blast Phase) 12/2020 - 09/2017
2	Hemorrhage 12/2020 - 01/2017
2	Lymphoma (Lymphomas) 01/2017 - 01/2010
2	Essential Thrombocythemia 06/2016 - 11/2012
2	Pruritus (Itching) 12/2013 - 01/2012
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2011 - 04/2005
2	Chromosome Aberrations (Chromosome Abnormalities) 02/2009 - 02/2007
1	COVID-19 08/2022
1	Cutaneous Mastocytosis 01/2021
1	Osteoporosis 01/2021
1	Drug-Related Side Effects and Adverse Reactions 12/2020
1	Opportunistic Infections (Opportunistic Infection) 12/2020
1	Lung Diseases (Lung Disease) 01/2020

Drug/Important Bio-Agent (IBA)

21	Imatinib Mesylate (Gleevec)FDA Link 12/2020 - 07/2004
15	Tryptases (Tryptase)IBA 01/2022 - 08/2014
11	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 09/2005
9	Pharmaceutical PreparationsIBA 01/2022 - 04/2005
8	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 09/2017 - 02/2007
7	ruxolitinibIBA 08/2022 - 03/2013
7	midostaurinIBA 01/2022 - 09/2013
7	Phosphotransferases (Kinase)IBA 10/2021 - 02/2007
6	Tyrosine Kinase InhibitorsIBA 02/2022 - 01/2011
5	avapritinibIBA 11/2022 - 01/2019
4	Syntex adjuvant formulationIBA 12/2017 - 11/2012
4	Hydroxyurea (Hydrea)FDA LinkGeneric 10/2016 - 01/2002
4	Interferon-alpha (Interferon Alfa)IBA 10/2016 - 01/2002
4	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 02/2009 - 10/2006
3	Immunoglobulin E (IgE)IBA 01/2022 - 06/2019
3	Biomarkers (Surrogate Marker)IBA 10/2021 - 10/2014
3	CytokinesIBA 01/2021 - 04/2012
3	Dasatinib (BMS 354825)FDA Link 01/2020 - 08/2011
3	nilotinib FDA Link 01/2020 - 12/2013
3	Hemoglobins (Hemoglobin)IBA 11/2019 - 09/2015
3	Codon (Codons)IBA 06/2019 - 08/2013
3	Tyrosine (L-Tyrosine)FDA Link 01/2012 - 02/2007
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 02/2011
2	Cladribine FDA LinkGeneric 01/2022 - 10/2016
2	mepolizumabIBA 01/2022 - 12/2021
2	Genetic Markers (Genetic Marker)IBA 01/2022 - 07/2004
2	Janus Kinase 2IBA 01/2021 - 03/2009
2	Alkaline PhosphataseIBA 01/2021 - 12/2019
2	InterferonsIBA 10/2016 - 01/2010
2	SteroidsIBA 06/2016 - 10/2006
2	Immunologic Factors (Immunomodulators)IBA 06/2016 - 02/2011
2	DNA (Deoxyribonucleic Acid)IBA 08/2012 - 04/2005
2	Pyridinolcarbamate (P23)IBA 01/2011 - 04/2005
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 05/2010 - 06/2006
2	Messenger RNA (mRNA)IBA 05/2010 - 10/2006
1	SARS-CoV-2 spike proteinIBA 08/2022
1	Rituximab (Mabthera)FDA Link 08/2022
1	BNT162 VaccineIBA 08/2022
1	2019-nCoV Vaccine mRNA-1273IBA 08/2022
1	venetoclaxIBA 02/2022
1	S63845IBA 02/2022
1	Monoclonal AntibodiesIBA 02/2022
1	Arthropod VenomsIBA 01/2022
1	Contrast MediaIBA 01/2022
1	Biological ProductsIBA 01/2022
1	Growth Factor ReceptorsIBA 12/2021
1	Telomerase (Telomerase Reverse Transcriptase)IBA 10/2021
1	imetelstatIBA 10/2021
1	NucleotidesIBA 01/2021
1	nintedanibIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	Interleukin-13IBA 01/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021
1	VaccinesIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2020

Therapy/Procedure

24	Therapeutics 01/2022 - 01/2002
6	Stem Cell Transplantation 01/2018 - 01/2002
5	Hematopoietic Stem Cell Transplantation 01/2017 - 06/2007
3	Drug Therapy (Chemotherapy) 01/2020 - 01/2002
2	Premedication 01/2022 - 01/2021
2	Precision Medicine 01/2020 - 06/2019
2	Erythrocyte Transfusion 12/2017 - 01/2017